Ingevity (NYSE:NGVT – Get Free Report) will issue its quarterly earnings data after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of $0.60 per share for the quarter. Ingevity has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.
Ingevity (NYSE:NGVT – Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $1.01 EPS for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.04). Ingevity had a positive return on equity of 19.59% and a negative net margin of 27.85%. The business had revenue of $390.60 million for the quarter, compared to analyst estimates of $407.58 million. During the same quarter last year, the firm earned $1.41 earnings per share. The firm’s quarterly revenue was down 18.9% compared to the same quarter last year. On average, analysts expect Ingevity to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Ingevity Stock Up 4.5 %
Shares of NGVT stock opened at $33.65 on Monday. Ingevity has a 12 month low of $30.90 and a 12 month high of $56.29. The firm has a market cap of $1.22 billion, a PE ratio of -2.83 and a beta of 1.62. The stock has a 50 day moving average of $36.67 and a 200-day moving average of $42.58. The company has a quick ratio of 1.07, a current ratio of 1.92 and a debt-to-equity ratio of 4.92.
Analyst Ratings Changes
Get Our Latest Research Report on NGVT
About Ingevity
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Featured Stories
- Five stocks we like better than Ingevity
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 3 Healthcare Dividend Stocks to Buy
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.